Director
DIN: 10832827
Rakshit Rajendrakumar Shah is currently associated with 3 companies in various capacities such as Partner, Designated Partner and Director. They serve as a Director at AROGYAM CANCER AND SUPERSPECIALITY HOSPITAL LLP and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 10832827.Rakshit Rajendrakumar Shah is currently involved in 3 different roles. Their most recent position is with GUJARAT CANCER AND SUPERSPECIALITY HOSPITAL PRIVATE LIMITED as a Director. The first company Rakshit Rajendrakumar Shah was appointed to as a director was AROGYAM CANCER AND SUPERSPECIALITY HOSPITAL LLP. Rakshit Rajendrakumar Shah is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
Rakshit Rajendrakumar Shah is currently associated with 3 companies in various capacities such as Partner, Designated Partner and Director. They serve as a Director at AROGYAM CANCER AND SUPERSPECIALITY HOSPITAL LLP and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 10832827.Rakshit Rajendrakumar Shah is currently involved in 3 different roles. Their most recent position is with GUJARAT CANCER AND SUPERSPECIALITY HOSPITAL PRIVATE LIMITED as a Director. The first company Rakshit Rajendrakumar Shah was appointed to as a director was AROGYAM CANCER AND SUPERSPECIALITY HOSPITAL LLP. Rakshit Rajendrakumar Shah is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
3
Male
India
Call +91 81049 46419 and we'll pull the verified contact details for you.
Current Companies (1)
Current LLPs (2)
Past Companies (0)
9 Months 5 Months Interval
| Company Name | Designation | Date of Appointment |
|---|---|---|
| GUJARAT CANCER AND SUPERSPECIALITY HOSPITAL PRIVATE LIMITED | Director | 30-Jun-2026 |